Who owns Maze Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of MAZE from SEC Form 13F filings across 160 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 160 institutions disclosed 58.4M shares of Maze Therapeutics, Inc. worth $1.74B — about 98.9% of shares outstanding; the largest disclosed holder is Frazier Life Sciences Management, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
160
13F holders
$1.74B
value, 2026 filers
98.9%
of shares outstanding (58.4M sh)
38
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of MAZE's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 5.0M | $150.2M | 3.3% | 8.5% | +10.2% |
| 2 | TRV GP IV, LLC | 4.5M | $133.5M | 52.6% | 7.6% | 0.0% |
| 3 | ARCH Venture Management, LLC | 4.1M | $123.0M | 11.2% | 7% | 0.0% |
| 4 | Deep Track Capital, LP | 3.7M | $111.4M | 1.6% | 6.3% | +7.3% |
| 5 | BlackRock, Inc. | 3.5M | $104.5M | 0.0% | 5.9% | +36.3% |
| 6 | Jupiter Topco LLCNEW | 3.4M | $101.8M | 0.0% | 5.8% | new |
| 7 | T. Rowe Price Investment Management, Inc.NEW | 2.6M | $77.7M | 0.1% | 4.4% | new |
| 8 | Logos Global Management LP | 1.9M | $57.7M | 2.5% | 3.3% | +56.7% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 1.8M | $53.1M | 0.0% | 3% | +23.9% |
| 10 | a16z Capital Management, L.L.C. | 1.7M | $50.8M | 0.4% | 2.9% | 0.0% |
| 11 | Venrock Adviser, LLC | 1.6M | $47.8M | 1.4% | 2.7% | 0.0% |
| 12 | Alphabet Inc. | 1.4M | $41.4M | 0.0% | 2.4% | 0.0% |
| 13 | BRAIDWELL LPNEW | 1.1M | $34.0M | 1.3% | 1.9% | new |
| 14 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 1.1M | $33.1M | 0.2% | 1.9% | +197.0% |
| 15 | FMR LLC | 1.1M | $31.5M | 0.0% | 1.8% | +22.3% |
| 16 | General Catalyst Group Management, LLC | 1.0M | $30.9M | 16.4% | 1.8% | 0.0% |
| 17 | STATE STREET CORP | 997,533 | $29.8M | 0.0% | 1.7% | +56.7% |
| 18 | JPMORGAN CHASE & CO | 964,011 | $28.0M | 0.0% | 1.6% | +1549.4% |
| 19 | Driehaus Capital Management LLC | 954,886 | $28.5M | 0.2% | 1.6% | +50.1% |
| 20 | TRV GP V, LLC | 950,800 | $28.4M | 5.7% | 1.6% | 0.0% |
| 21 | MARSHALL WACE, LLP | 914,572 | $27.3M | 0.0% | 1.6% | +194.4% |
| 22 | GEODE CAPITAL MANAGEMENT, LLC | 858,054 | $25.6M | 0.0% | 1.5% | +43.0% |
| 23 | CITADEL ADVISORS LLC | 852,676 | $25.4M | 0.0% | 1.4% | +9.9% |
| 24 | Casdin Capital, LLC | 843,857 | $25.2M | 1.3% | 1.4% | +11.2% |
| 25 | ArrowMark Colorado Holdings LLC | 767,383 | $22.9M | 1.0% | 1.3% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.